Skip to main content

Table 2 Most common adverse events (AEs) attributed to study therapy

From: A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

 

AE name

Number of events

Number of subjects

% of subjects

Grade 1

Grade 2

Grade 3

Grade 4

1

Fatigue

14

13

81

13

1

0

0

2

Nausea

12

11

69

11

0

0

0

3

Peripheral sensory neuropathy

8

8

50

6

2

0

0

4

Neutrophil count decrease

7

6

38

0

1

5

1

5

Peripheral motor neuropathy

7

6

38

7

0

0

0

6

Constipation

6

6

38

6

0

0

0

7

Alopecia

6

6

38

5

1

0

0

8

Dyspnea

5

3

19

5

0

0

0

9

Diarrhea

4

4

25

4

0

0

0

10

Flu like symptoms

4

3

19

3

0

1

0